News

Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...
The plans amount to an extraordinary flex of Robert F. Kennedy Jr.’s power as health secretary to make decisions ordinarily ...
There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...
The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...
The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.
By Julie Steenhuysen CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good ...
Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...
“Under Secretary Kennedy’s leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to ...
A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...
Former government health officials fear the Trump administration is moving to slow-walk vaccine approvals, including by ...
If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...
Speaking at Semafor's World Economy Summit, Marty Makary diverged from Robert F. Kennedy Jr.’s stance on vaccine ...